Q1 FY27 results: revenue down 17% YoY, loss widens

Revenue DeclinePat NegativeResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-13.8%Reaction day

₹43.00

prior close

₹38.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-13.8% vs market

Pharmaceuticals peers, median of 165sector-0.1%-13.8% vs sector

On the reaction day the stock moved 13.8 pts less than Nifty Microcap 250 and 13.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.4

10m

+3.4

15m

-0.3

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-13.8-0.1-13.8-0.1-13.8

Next day

-13.7-0.2-13.5+0.0-13.8

-8.6+0.1-8.8-0.0-8.6

-14.0+0.3-14.3+0.3-14.3

-10.0+0.4-10.4-0.5-9.5

-7.6+0.5-8.1-1.1-6.4

-16.3+0.3-16.5-1.8-14.4

15d

-10.3+1.9-12.2+0.2-10.6

-10.4+2.2-12.6+1.7-12.1

-3.5-1.2-2.3-1.8-1.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gujarat Terce Laboratories reported Q1 FY27 results with revenue from operations at Rs 900.24 lakh, down about 17% YoY from Rs 1085.36 lakh. Total expenses rose to Rs 963.35 lakh, pushing pre-tax loss to Rs 14.88 lakh versus Rs 7.10 lakh loss YoY. PAT stood at negative Rs 17.81 lakh versus negative Rs 4.35 lakh YoY. EPS was minus 0.23. Auditor issued an unmodified limited review report.

Likely market impact

Performance worsened: revenue declined and losses deepened versus the year-ago quarter, raising concerns on near-term trajectory.